Leuprorelin Sandoz (Leuprorelin)

Leuprorelin is a synthetic GnRH analogue that binds to pituitary GnRH receptors. After an initial hormone surge, the receptors become desensitized, leading to a sustained fall in luteinizing hormone (LH) and follicle‑stimulating hormone (FSH). The resulting drop in testosterone or estrogen levels underlies its therapeutic effect.

The exact dose and dosing interval are determined by the prescribing clinician based on the specific indication, patient weight, disease stage, and treatment goals. Leuprorelin is available in various strengths for subcutaneous injection, and the prescriber selects the appropriate regimen for each individual.

Leuprorelin is generally contraindicated in pregnancy because it can interfere with normal hormonal development of the fetus. Women of child‑bearing potential should use effective contraception during treatment and for a period after the last dose. Limited data are available for breastfeeding, so use is not recommended without specialist advice.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Leuprorelin Sandoz. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Leuprorelin belongs to the GnRH agonist class, which initially causes a hormone flare before suppressing gonadotropins. Compared with GnRH antagonists, which block receptors without a flare, leuprorelin may require short‑term management of initial symptom worsening. Its efficacy and safety profile are comparable to other approved agonists such as goserelin and triptorelin.

Leuprorelin Sandoz should be stored at 2‑8 °C (refrigerated). Keep the vials in the original packaging, protect them from light, and avoid freezing or shaking. If temporary storage at controlled room temperature is unavoidable, limit exposure to no more than 30 days and follow the manufacturer’s guidance.

Leuprorelin Sandoz is supplied as a sterile solution for subcutaneous injection. A healthcare professional administers the dose into the fatty tissue of the abdomen, thigh, or upper arm using aseptic technique. Injection sites should be rotated to reduce local irritation, and the medication is typically given at intervals ranging from monthly to quarterly, as prescribed.

Serious adverse events include cardiovascular complications such as myocardial infarction or stroke, severe bone loss leading to osteoporosis or fractures, and a potential disease flare during the initial hormone surge. Patients should be monitored regularly for cardiac symptoms, bone density changes, and any unexpected worsening of their underlying condition.

Leuprorelin Sandoz is contraindicated in patients with known hypersensitivity to leuprorelin or any excipients, in women who are pregnant or planning pregnancy, and in individuals with uncontrolled cardiovascular disease where hormone suppression could exacerbate risk. Clinicians should also exercise caution in patients with severe osteoporosis or active bone metastases.